文献速递乳腺MR

基于MRI的新型超融合放射组学预测乳腺癌新辅助治疗病理完全缓解

Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.
PubMed 文献 · Acad Radiol · 2025-01-06

研究提出基于MRI的超融合放射组学方法,用于预测乳腺癌新辅助治疗后的病理完全缓解。在两个中心纳入治疗前动态增强MRI和超多b值扩散加权成像数据,训练集547例、外部测试集295例。超融合模型AUC为0.81-0.85,优于常规模型AUC 0.74-0.80;复合模型AUC 0.88-0.93,优于超融合模型和常规模型。

要点

  • 超融合放射组学模型预测pCR的AUC为0.81-0.85,优于常规放射组学模型的0.74-0.80。
  • 整合超融合与常规特征的复合模型AUC达0.88-0.93,判别能力进一步提升。
  • 超融合放射组学标签和复合放射组学标签均为pCR的独立预测因素。

核心结论

  • 超融合放射组学方法预测新辅助治疗pCR的性能显著优于常规放射组学方法,超融合放射组学特征在常规特征之外提供了增量判别价值,生成的超融合放射组学标签是pCR的独立预测因素。

研究设计与样本

  • 研究论文;在两个中心纳入接受新辅助治疗后手术的乳腺癌患者,训练集(中心1)547例、外部测试集(中心2)295例;采集治疗前动态增强MRI和超多b值扩散加权成像数据,提取超融合放射组学特征与常规放射组学特征,经特征选择后用逻辑回归构建超融合模型、常规模型及整合两者的复合模型,以AUC评估性能,并用多变量逻辑回归分析pCR相关变量。

诊断标准与关键数值

  • 超融合模型预测pCR的AUC为0.81-0.85,优于常规模型的AUC 0.74-0.80(p<0.05);复合模型AUC为0.88-0.93,优于超融合模型和常规模型(p<0.05);超融合放射组学标签的比值比为5.70-12.98(p<0.05),复合放射组学标签的比值比为1.57-7.71(p<0.05),在训练集和外部测试集中均与pCR独立相关。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To propose a novel MRI-based hyper-fused radiomic approach to predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer (BC).

MATERIALS AND METHODS: Pretreatment dynamic contrast-enhanced (DCE) MRI and ultra-multi-b-value (UMB) diffusion-weighted imaging (DWI) data were acquired in BC patients who received NAT followed by surgery at two centers. Hyper-fused radiomic features (RFs) and conventional RFs were extracted from DCE-MRI or UMB-DWI. After feature selection, the following models were built using logistic regression and the retained RFs: hyper-fused model, conventional model, and compound model that integrates the hyper-fused and conventional RFs. The output probability of each model was used to generate a radiomic signature. The model's performance was quantified by the area under the receiver-operating characteristic curve (AUC). Multivariable logistic regression was used to identify variables (clinicopathological variables and the generated radiomic signatures) associated with pCR.

RESULTS: The training/external test set (center 1/2) included 547/295 women. The hyper-fused models (AUCs=0.81-0.85) outperformed (p<0.05) the conventional models (AUCs=0.74-0.80) in predicting pCR. The compound models (AUCs=0.88-0.93) outperformed (p<0.05) the hyper-fused models and conventional models for pCR prediction. The hyper-fused radiomic signatures (odds ratios=5.70-12.98; p<0.05) and compound radiomic signatures (odds ratios=1.57-7.71; p<0.05) were independently associated with pCR. These are true for the training and external test sets.

CONCLUSION: The hyper-fused radiomic approach had significantly better performance for predicting pCR to NAT than the conventional radiomic approach, and the hyper-fused RFs provided incremental discrimination of pCR beyond the conventional RFs. The generated hyper-fused radiomic signatures were independent predictors of pCR.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Cui QX, Zhou LQ, Wang XY, et al. Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer. Acad Radiol. 2025. PMID: 39765433. doi:10.1016/j.acra.2024.12.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。